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Objectives We sought to evaluate the outcomes and identify risk factors for mortality after heart transplantation (HT) for
congenital heart disease (CHD) in infants, children, and adults.
Background CHD is considered a risk factor for mortality after HT, yet this unique group of patients represents a spectrum of
complexity.
Methods There were 488 patients transplanted for CHD from the combined Pediatric Heart Transplant Study (1993 to
2002, n  367) and the Cardiac Transplant Registry Database (1990 to 2002, n  121) who were analyzed.
Results The median age at HT was 12.4 years. Primary diagnosis included single ventricle (36%), d-transposition of the great
arteries (12%), right ventricular outflow tract lesions (10%), l-transposition of the great arteries (8%), ventricular/atrial
septal defects (8%), left ventricular outflow obstruction (8%), and other (18%). Ninety-three percent of patients had at
least 1 operation before HT. Survival at 3 months post-HT was significantly worse in CHD patients versus children with
cardiomyopathy, but not adults with cardiomyopathy (86%, 94%, and 91%, respectively). There was no difference in
conditional 3-month survival among the 3 groups. Five-year survival was 80%. Risk factors for early mortality were
older recipient age, older donors with longer ischemic times, and pre-HT Fontan operations. Predicted survival in Fon-
tan patients was lower (77% and 70% at 1 and 5 years) versus non-Fontan patients (88% and 81% at 1 and 5 years).
Risk factors for constant phase mortality included younger recipient age, higher transpulmonary gradient, cytomega-
lovirus mismatch at HT, and earlier classical Glenn operation.
Conclusions Patients undergoing transplantation for CHD have a good late survival if they survive the early post-operative
period. Risk factors for reduced survival are older age at transplant and a previous Fontan operation. (J Am
Coll Cardiol 2009;54:160–5) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.020t
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Cong-term survival in children and adults with congenital
eart disease (CHD) has improved markedly with advances
n medical and surgical therapies. Despite these advances, a
rowing number of patients with complex CHD will
ltimately require heart transplantation (HT) for end-stage
eart failure. CHD has been identified as a risk factor for
-year outcome after transplantation (1), but studies iden-
rom the *Department of Pediatric Cardiology, Columbia University, New York,
ew York; †Department of Cardiovascular Surgery, Emory University, Atlanta,
eorgia; ‡Department of Cardiovascular Surgery, University of Alabama, Birming-
am, Alabama; §Department of Pediatric Cardiology, Children’s Hospital of Penn-
ylvania, Philadelphia, Pennsylvania; University of Arkansas, Little Rock, Arkansas;
nd the ¶Department of Cardiology, St. Francis Medical Center, Peoria, Illinois.p
Manuscript received July 5, 2007; revised manuscript received March 25, 2009,
ccepted April 2, 2009.ifying specific risk factors for poor outcome after transplan-
ation for CHD in the combined adult and pediatric
opulation have not been performed.
The PHTS (Pediatric Heart Transplant Study) and the
TRD (Cardiac Transplant Research Database) are pro-
pective, event-driven registries that collect information
rom the time of listing for transplant in patients 18 years
f age (PHTS) and the time of transplant in patients 18
ears of age (CTRD) (2). The purpose of this study was to
se the data available from the PHTS and CTRD registries
o generate a combined dataset that would enable evaluation
f outcomes after HT in patients of all ages with end-stage
HD and to identify risk factors for mortality after trans-
lantation in this group.
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July 7, 2009:160–5 Transplant in Patients With CHDThis study is a retrospective multi-institutional analysis of
merged dataset generated from the CTRD and PHTS
egistries. The CTRD population consisted of 7,345 pa-
ients 18 years of age transplanted at 35 centers from
anuary 1990 through December 2002. The PHTS popu-
ation consisted of 923 patients18 years of age at the time
f listing for HT. A total of 366 patients 6 months of age
ere excluded to eliminate 291 (80%) of the infants under-
oing HT as a primary surgical procedure. Of the remaining
0%, some of whom were listed for transplantation and
nderwent palliative procedures while awaiting suitable
onor organs, all needed transplant 6 months after their
ast surgical procedure. This unique group of infants was
hought not to be generalizable to the entire cohort of
ediatric and adult patients with CHD undergoing trans-
lantation. The outcomes of infants with hypoplastic left
eart syndrome listed for cardiac transplantation using this
ame registry data have been published previously (3).
ethods
atients with the diagnosis of CHD who underwent HT
ere identified. Multiple recipient and donor variables were
xamined to identify risk factors for survival after transplan-
ation. Recipient variables included CHD diagnosis, United
etwork for Organ Sharing status at transplantation, sur-
ical history, and listing hemodynamics. Pulmonary vascular
esistance and percent reactive antibody data were not
vailable for analysis. Donor variables included echocardio-
raphic and angiographic data, cause of death, inotropic
upport, and cytomegalovirus mismatch. Data were ana-
yzed using Kaplan-Meier survival and nonparametric and
arametric hazard models. Survival was compared among
atients with CHD and those with cardiomyopathy 18
nd 18 years of age. Risk factors for death among the
atients with CHD were identified using multivariable
nalysis in the parametric hazard domain.
esults
here were 488 patients (121 of 7,345 [1.6%] patients in
he CTRD and 367 of 923 [40%] patients in the PHTS
atabase) with the diagnosis of CHD who underwent HT
uring the study period. Total patient-years of follow-up
ere 442 in the adult patients and 1,095 in the pediatric
atients. Median follow-up was 2.3 years for the entire
ohort and 3.3 years for surviving patients. The age distri-
ution of the patients is represented in Figure 1. The mean
ge was 14.8 years, with a median of 12.4 years and a range
f 6 months to 62 years. There were 29 patients older than
0 years.
The major diagnostic categories are shown in Table 1.
ingle ventricle patients (36%) represented the largest
roup. Patients with a systemic right ventricle (d-
ransposition of the great arteries [TGA] and l-TGA)
epresented 20% of the population. Right outflow tract
esions, most commonly tetralogy of Fallot, were present in0% of the population. Other
iagnoses were equally distrib-
ted among ventricular and atrial
eptal defects, left ventricular
utflow tract lesions, and atrio-
entricular canal defects.
The last major surgical opera-
ion performed before HT is il-
ustrated in Figure 2; 454 (93%)
f patients had at least 1 operation before transplantation.
he average time from last operative procedure to HT for
atients in the PHTS registry was 3.9  4.2 years. There is
o data field for this information in the CTRD. Four-
hamber repairs were performed in 142 (29%) patients, with
n additional 49 (10%) patients undergoing Mustard pro-
edures. The Fontan operation was the last surgical proce-
ure in 107 patients, representing 22% of the CHD popu-
ation. The mean age at transplant in the Fontan patients
as 15 years. Staged palliation for single ventricle, including
he Norwood procedure or variants of the Glenn procedure,
as the last operation performed before transplantation in
pproximately 20% of patients.
Figure 3 compares the Kaplan-Meier post-transplant
urvival of patients with CHD of any age with adult and
ediatric patients with cardiomyopathy. Survival in the
HD patients was significantly worse than survival in
ediatric patients with cardiomyopathy (p  0.01) and no
ifferent from that in adults with cardiomyopathy (p 
.07). Survival at 3 months was 86% for patients with
HD, 91% for adults with cardiomyopathy, and 94% for
hildren with cardiomyopathy. Conditional survival of pa-
ients who survived the initial 3 months post-transplant is
hown in Figure 4. Conditional 3-month survival was not
ignificantly different among these groups. Five-year sur-
ival was approximately 80%.
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Figure 1 Age Distribution
Age distribution in 488 patients undergoing heart transplantation for congenital
heart disease. CTRD  Cardiac Transplant Research Database; PHTS  Pedi-
atric Heart Transplant Study.
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CHD  congenital heart
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HT  heart transplantation
TGA  transposition of the
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Transplant in Patients With CHD July 7, 2009:160–5In patients with CHD, Kaplan-Meier survival differed
mong the diagnostic groups. The patients with TGA had
he highest survival and patients with atrioventricular canal
efect demonstrated the worst survival: 88% versus 62%,
espectively (p  0.02). Survival was significantly worse
ith increasing ischemic times (p  0.02). The mean
schemic time was 228 min for patients having 1 to 2
revious sternotomies and 242 min for patients having 3
ternotomies. An interaction was seen among recipient age,
onor age, and ischemic time, with the predicted probability
f death increasing in the older recipients with respect to
lder donor age and longer ischemic time. A 40-year-old
ecipient who received a 50-year-old donor heart and had a
-h ischemic time had a 15% probability of death within 1
ear, compared with a 40% probability of death within 1
ear if that donor’s ischemic time was 5 h.
The results of multivariable analysis for risk factors
ssociated with both early and constant phase death in
atients with CHD are shown in Table 2. During the early
hase after transplantation, older recipient age at transplant
30 years vs. 10 years) had a 1.5-fold increased risk of death,
ong ischemic time (300 min vs. 180 min for a 20-year-old
onor) had a 1.6-fold increased risk, and older donor age in
7% unoperated10% Mustard
11% Bands/shunts
5% Norwood
29% 4-chamber 
repair
16% Glenn
22% Fontan
Figure 2 Last Major Surgical Operation
Last major surgical procedure
performed before heart transplantation (n  488).
ajor Diagnostic Categories for Congenital Heartisease Patients Und rgoing Heart Tra splant tion
Table 1 Major Diagnostic Categories for Congenital HeartDisease Patients Undergoing Heart Transplantation
Diagnosis n % (of 488)
Single ventricle 176 36
d-transposition of the great arteries 58 12
Right ventricular outflow tract lesions 49 10
Ventricular/atrial septal defect 38 8
Left ventricular outflow tract lesions 38 8
l-transposition of the great arteries 39 8
Complete atrioventricular canal defect 37 8
Other 53 11
Total 488 100ombination with a long ischemic time (35 years vs. 12 years
t 300 min) had a 1.4-fold increased risk.
Having a previous Fontan procedure increased the rela-
ive risk of death to 8.6. Figure 5 compares the survival
ost-transplant of Fontan patients with all other patients
ith CHD having transplantation. One-year survival was
1% in the Fontan patients and 83% in the non-Fontan
HD patients. Five-year survival was 60% in the Fontan
atients and 74% in the non-Fontan patients.
In the constant phase, younger recipient age increased the
isk of late death post-transplant. Figure 6 shows a stratified
ctuarial by age. Patients transplanted between the ages of 6
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Figure 3 Post-Transplant Survival:
CHD Versus Non-CHD by Age
Kaplan-Meier post-transplant survival of patients with congenital heart disease
(CHD) of any age compared with adult and pediatric patients with cardiomyopa-
thy. The vertical bars surrounding the survival estimates represent 70% confi-
dence limits.
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Figure 4 Conditional Survival: CHD Versus Non-CHD by Age
Conditional survival of patient who survived the initial 3 months post-
transplant. There is no difference among the 3 groups. The vertical bars sur-
rounding the survival estimates represent 70% confidence limits. CHD  con-
genital heart disease.
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July 7, 2009:160–5 Transplant in Patients With CHDnd 12 years had a 28% decline in survival in the 6 to 8 years
fter transplantation; patients20 years of age at transplant
ad similar 1-, 3-, and 5-year survival rates. Other risk
actors for mortality in the constant phase included a higher
ystolic transpulmonary gradient, cytomegalovirus mis-
atch in a negative recipient at the time of transplant, and
n earlier classical Glenn operation.
iscussion
his large multicenter study evaluated outcomes after HT
n 488 children 6 months of age and adults with CHD
nd identified risk factors for early and constant phase
ortality. The ability to undertake cardiac transplantation
ith complex CHD has been in evolution.
Transplantation for CHD was first reported in 1967 and
nvolved an infant with complex CHD (4). Multiple sub-
equent reports have addressed the surgical techniques
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p = .006
Fontan (n=107)
Non-Fontan (n=381)
Figure 5 Post-Transplant Survival: Fontan Versus Non-Fontan
Kaplan-Meier survival comparing the survival post-transplant of Fontan patients
with all other patients transplanted with congenital heart disease. The vertical
bars surrounding the survival estimates represent 70% confidence limits.
ultivariable Analysis for Risk Factors Associatedith Both Early Phase and Constant Pha eor ality in Patients With Congeni al Heart Disease
Table 2
Multivariable Analysis for Risk Factors Associated
With Both Early Phase and Constant Phase
Mortality in Patients With Congenital Heart Disease
Variable Relative Risk p Value
Early phase
Older recipient age 1.5 0.02
Previous Fontan operation 8.6 0.003
Longer ischemic time 1.6 0.002
Interaction of donor age and ischemic time 1.4 0.0007
Higher pre-Tx mean RAP (only in patients
without previous Fontan)
2.4 0.0001
Constant phase
Younger recipient age 1.8 0.0001
Higher systolic transpulmonary gradient 2.0 0.01
CMV donor, CMV recipient 2.8 0.001
Previous classical Glenn operation 3.1 0.01
MV  cytomegalovirus; RAP  right atrial pressure; Tx  transplant.bequired for transplantation in this setting (5–9). HT is
ncreasingly considered a treatment option for patients with
HD and end-stage heart failure. According to the registry
f the International Society of Heart and Lung Transplan-
ation, children with CHD account for 47% of the pediatric
atients undergoing HT (1).
This study demonstrated an early difference in survival
etween patients with CHD who underwent transplanta-
ion compared with pediatric patients with cardiomyopathy.
hree-month survival post-transplant was significantly
orse in the patients with CHD compared with pediatric
atients with cardiomyopathy, but not with adults with
ardiomyopathy. Analysis from the International Society of
eart and Lung Transplantation also identified CHD as a
isk factor for 1-year mortality, but the finding of increased
isk in older recipients and Fontan patients was not shown
n that dataset. In our analysis, conditional survival in
atients who survived the first 3 months after transplant was
o different among the groups, indicating that the increased
isk of mortality is likely related to peri-transplant issues.
everal single-center studies have identified no increased
arly risk after transplantation for CHD compared with
ther conditions (7,10,11). However, the power of these
nalyses was limited by smaller sample sizes.
Although transplantation for adults with acquired heart
isease and end-stage heart failure has become routine,
xperience with HT in adults with CHD is sparse. As
urvival among patients with CHD improves, more such
atients can be expected to present for consideration for HT
s a final treatment option. According to the registry of the
nternational Society of Heart and Lung Transplantation,
% of adults undergoing HTs have CHD as an indication
or transplant (12). Experience with adults and CHD has
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Figure 6 Post-Transplant Survival:
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Kaplan-Meier post-transplant survival of patients with congenital heart disease
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Transplant in Patients With CHD July 7, 2009:160–5eported survival rates (8,13,14). Lamour et al. (15) reported
esults of 24 adult patients with CHD, one-half of whom
ad single-ventricle anatomy. Survival in this series was 79%
t 1 year and 60% at 5 years. In this small series, there was
o anatomic or surgical risk factor that could be identified as
redictive of death, although 4 of 5 early deaths were in
atients who had single-ventricle anatomy. More recently,
hen et al. (16), from the same institution, reported
xperience with combined pediatric and adult patients with
HD undergoing HT. There was a significant difference in
0-day mortality between CHD patients and the entire
ohort. However, the long-term survival of patients with
nd without CHD was comparable. Since 1990, 1- and
-year survivals were 82% and 77%, respectively. The
ajority of deaths were intraoperative or related to bleeding.
A striking finding in this study was the degree of risk
ound in HT patients with an earlier Fontan procedure. As
he number of patients surviving single-ventricle initial
alliation and subsequent Fontan procedure increases, the
nown propensity for late cardiac failure post-Fontan will
ikely generate a growing subset of transplant recipients.
lthough cause of death was not analyzed in this study, one
an speculate from other smaller studies why this degree of
isk was found in our study. Other studies (8,16–18) and in
articular, the Fontan analysis within the Pediatric Heart
ransplant database (19), underscores the complexity of
hese patients. These complexities are not only associated
ith the technical challenges related to individual anatomy
nd multiple earlier palliative procedures, but also to diffi-
ulty in evaluating pulmonary vascular resistance and an
ncreased propensity for infection and bleeding in Fontan
atients.
Pulmonary vascular resistance in many complex CHD
atients and Fontan patients is difficult to assess and was not
nalyzed in this study. Anomalies within the pulmonary
asculature or dual supplies of pulmonary blood flow may
ake accurate calculations of resistance impossible. In
ddition, patients with sluggish blood flow to the pulmo-
ary arteries or loss of hepatic blood flow are at risk for
icroemboli and arteriovenous malformations that may
hange the distribution of flow to the right and left lung. It
ay be erroneous to assume that because a Fontan patient
s alive, the pulmonary vascular resistance is low enough to
olerate an HT (20).
Bernstein et al. (19) noted Fontan patients had a trend
oward increased risk of death from infection: 30% versus 21%
n CHD patients and 13% in non-CHD patients. Patients
ith a failed Fontan and, in particular, those with protein-
osing enteropathy, are generally cachetic, edematous, and
ymphopenic, which predisposes them to infection. This in-
ection risk is increased by the introduction of immunosup-
ression immediately after transplantation and may explain the
ncrease in infection seen in Fontan patients after transplanta-
ion. A trend toward increased early graft failure, hemorrhage,
nd technical and operative deaths in these Fontan patients
as also noted in this study. In the previously cited study byamour et al. (15), 4 of 5 early deaths were in Fontan patients.
hree of these patients had significant surgical bleeding,
esulting in 2 deaths. The presence of aortopulmonary collat-
rals in some Fontan patients and vascular adhesions after
ultiple operations may increase the risk for bleeding. In
ddition, many Fontan patients had some degree of hepatic
ysfunction, which could increase the likelihood of post-
perative coagulopathy.
Although recipient preformed antibody data were not
vailable, CHD patients with multiple reoperations and
ransfusions and the possibility of homograft material being
sed in some repairs increase the risk of pre-sensitization,
hich could affect early graft function and increase the
ikelihood of early graft failure (21,22). Neither database
dentified whether the surgeons performing HT on these
HD patients were trained congenital cardiac surgeons.
ne could speculate that this might influence surgical
utcomes. In addition, associated genetic disorders are not
ell captured in the databases. Although this population
ikely represents a small number of patients, this too may
nfluence outcome after HT. As these databases evolve,
nclusion of these data fields would improve our dataset and
llow these factors to be analyzed in assessing outcome after
ransplantation in patients with CHD.
The finding of young recipient age as a risk factor in the
onstant phase contradicts other studies that suggest supe-
ior conditional long-term survival in infants 1 year of age
1). When survival is stratified by recipient age at transplant,
atients undergoing transplantation between 6 and 12 years
f age have a dramatic decrease in survival 6 to 8 years after
urgery. Decline in survival of transplant patients when they
each their teen and early adult years has also been reported
y others and is likely related to nonadherence. Late
ejection after transplantation is associated with nonadher-
nce and poor outcome (23,24).
onclusions
T for patients with CHD is an acceptable and encourag-
ng option for patients with end-stage heart failure. Once
ut of the initial post-operative period, survival is the same
s for patients without CHD. Risk factors for poor outcome
re older age at transplantation and a previous Fontan
peration. New strategies are needed to neutralize the
nderlying transplant risks unique to the failing Fontan
atient.
eprint requests and correspondence: Dr. Jacqueline M. Lam-
ur, Children’s Hospital at Montefiore, 3415 Bainbridge Avenue,
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